削减
发表于 2025-3-25 07:09:41
Imatinib: Clinical Pharmacology and Therapeutic Resultsssion-free survival and overall survival associated with imatinib therapy (400 mg daily) have ranged between 83–94% and 83–97%, respectively. Imatinib is generally well tolerated, and adverse events are typically manageable. Current evidence does not support the extensive use of high-dose imatinib (
MURKY
发表于 2025-3-25 08:05:47
Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Other TKIsce and intolerance to imatinib are frequently reported, particularly in patients with advanced-stage disease; this leads to around 30% of CML patients discontinuing imatinib treatment. Point mutations within the . kinase domain, which interfere with imatinib binding, are the most critical cause of i
清澈
发表于 2025-3-25 13:40:56
Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Basic Results and Pharmacokineticsms of action of rituximab include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis. The influences of CD20 expression level, circulating soluble CD20, Fcγ receptor (FcγR) polymorphisms, complement regulatory proteins, and C1qA-276 p
Obscure
发表于 2025-3-25 19:28:10
http://reply.papertrans.cn/23/2250/224970/224970_24.png
白杨鱼
发表于 2025-3-25 23:17:02
http://reply.papertrans.cn/23/2250/224970/224970_25.png
自制
发表于 2025-3-26 02:54:18
http://reply.papertrans.cn/23/2250/224970/224970_26.png
增长
发表于 2025-3-26 07:57:34
FLT3 Inhibitorson is the most frequent genetic alteration in acute myeloid leukemia (AML) and is associated with poor prognosis in AML patients. Since high-dose chemotherapy including allogeneic hematopoietic stem cell transplantation cannot overcome a poor prognosis, development of FLT3 inhibitor is highly expect
刺穿
发表于 2025-3-26 10:42:47
Retinoic Acid, All-, Retinoic Acid (ATRA), and Tamibaroteneete remission (CR) in patients with acute promyelocytic leukemia (APL). Although introduction of ATRA as a differentiating agent has been a major breakthrough in the treatment of APL, ATRA is currently recognized as a molecular-targeted therapy directed at the PML-RARα chimeric protein, which is gen
patriarch
发表于 2025-3-26 14:22:46
http://reply.papertrans.cn/23/2250/224970/224970_29.png
书法
发表于 2025-3-26 20:43:33
http://reply.papertrans.cn/23/2250/224970/224970_30.png